Novel protection and treatment strategies for chemotherapy-associated ovarian damage

被引:15
|
作者
Xiong, Jiaqiang [1 ,2 ]
Xue, Liru [1 ]
Li, Ya [1 ]
Tang, Weicheng [1 ]
Chen, Dan [1 ]
Zhang, Jinjin [1 ]
Dai, Jun [1 ]
Zhou, Su [1 ]
Lu, Zhiyong [3 ]
Wu, Meng [1 ]
Wang, Shixuan [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Obstet & Gynecol, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[2] Wuhan Univ, Dept Obstet & Gynecol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[3] Wuhan Univ Sci & Technol, Puren Hosp, Ctr Reprod Med, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
ANTI-MULLERIAN HORMONE; PRIMORDIAL FOLLICULAR RESERVE; STEM-CELLS; OOCYTE APOPTOSIS; BREAST-CANCER; IN-VITRO; FERTILITY; FOLLICLES; INFERTILITY; CYCLOPHOSPHAMIDE;
D O I
10.1530/EJE-20-1178
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fertility and ovarian protection against chemotherapy-associated ovarian damage has formed a new field called oncofertility, which is driven by the pursuit of fertility protection as well as good life quality for numerous female cancer survivors. However, the choice of fertility and ovarian protection method is a difficult problem during chemotherapy and there is no uniform guideline at present. To alleviate ovarian toxicity caused by anticancer drugs, effective methods combined with an individualized treatment plan that integrates an optimal strategy for preserving and restoring reproductive function should be offered from well-established to experimental stages before, during, and after chemotherapy. Although embryo, oocyte, and ovarian tissue cryopreservation are the major methods that have been proven effective and feasible for fertility protection, they are also subject to many limitations. Therefore, this paper mainly discusses the future potential methods and corresponding mechanisms for fertility protection in chemotherapy-associated ovarian damage.
引用
收藏
页码:R177 / R192
页数:16
相关论文
共 50 条
  • [1] Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage
    Guo, Yican
    Xue, Liru
    Tang, Weicheng
    Xiong, Jiaqiang
    Chen, Dan
    Dai, Yun
    Wu, Chuqing
    Wei, Simin
    Dai, Jun
    Wu, Meng
    Wang, Shixuan
    [J]. HUMAN REPRODUCTION UPDATE, 2024, 30 (05) : 614 - 647
  • [2] The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence
    Wu, Chuqing
    Wu, Tong
    Chen, Dan
    Wei, Simin
    Tang, Weicheng
    Xue, Liru
    Xiong, Jiaqiang
    Huang, Yibao
    Guo, Yican
    Chen, Ying
    Wu, Meng
    Wang, Shixuan
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [3] Treatment of chemotherapy-associated cardiomyopathy
    Cai, Amanda W.
    Taylor, Marian H.
    Ramu, Bhavadharini
    [J]. CURRENT OPINION IN CARDIOLOGY, 2019, 34 (03) : 296 - 302
  • [4] Goserelin reduces chemotherapy-associated ovarian failure
    Mayor, Susan
    [J]. LANCET ONCOLOGY, 2015, 16 (04): : E160 - E160
  • [5] CHEMOTHERAPY-ASSOCIATED ACUTE MYELOGENOUS LEUKEMIA AND OVARIAN CARCINOMA
    HAQUE, T
    LUTCHER, C
    FAGUET, G
    TALLEDO, O
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1976, 272 (02): : 225 - 228
  • [6] Chemotherapy-associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
    Veeder, Justin A.
    Hothem, Lauren N.
    Cipriani, Amber E.
    Jensen, Brian C.
    Rodgers, Jo E.
    [J]. PHARMACOTHERAPY, 2021, 41 (12): : 1066 - 1080
  • [7] Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia
    Al-Samkari, Hanny
    Kuter, David J.
    Goodarzi, Katayoon
    Marshall, Ariela L.
    [J]. BLOOD, 2016, 128 (22)
  • [8] Chemotherapy-Associated Hepatotoxicities
    White, Michael A.
    Fong, Yuman
    Singh, Gagandeep
    [J]. SURGICAL CLINICS OF NORTH AMERICA, 2016, 96 (02) : 207 - +
  • [9] Chemotherapy-associated steatohepatitis
    Meunier, Lucy
    Larrey, Dominique
    [J]. ANNALS OF HEPATOLOGY, 2020, 19 (06) : 597 - 601
  • [10] Chemotherapy-associated hematopoietic toxicity
    Kuhn, JG
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 : S4 - S7